苯那普利及己酮可可碱对阿霉素肾病大鼠的肾脏保护作用

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (7): 736-740.

苯那普利及己酮可可碱对阿霉素肾病大鼠的肾脏保护作用

杨沿浪, 张道友, 汪向明, 崔明春, 吴小东

皖南医学院附属弋矶山医院肾内科, 芜湖241001, 安徽

收稿日期:2008-11-17 修回日期:2009-05-20 出版日期:2009-07-26 发布日期:2020-10-30
作者简介:杨沿浪, 男, 硕士, 研究方向:慢性肾小球疾病。Tel:0553-2259319 　E-mail:yangyanlang@126.com
基金资助:
皖南医学院中青年教师基金(WK200602AF)

Renoprotective effect and mechanisms of benazepril and pentifylline on adriamycin nephropathy rats

YANG Yan-lang, ZHANG Dao-you, WANG Xiang-ming, CUI Ming-chun, WU Xiao-dong

Department of Nephrology, Wannan Medical College Affiliated Yijishan Hospital, Wuhu 241001, Anhui, China

Received:2008-11-17 Revised:2009-05-20 Online:2009-07-26 Published:2020-10-30

摘要/Abstract

摘要： 目的:探讨苯那普利、己酮可可碱及两药联合应用对阿霉素肾病大鼠的肾脏保护作用。方法:42 只SD 大鼠随机取出6 只大鼠为正常对照组, 余下经尾静脉注射阿霉素制备肾病模型, 正常对照组给予等量生理盐水注射。造模成功的大鼠(24 h 蛋白尿>100 mg) 随机分为模型组、血管紧张素转化酶抑制剂(ACEI) 组(苯那普利)、PTX 组(己酮可可碱)、联合治疗组(苯那普利加己酮可可碱)。8 周后处死大鼠, 经腹主动脉取血, 检查生化指标;取肾皮质作HE 染色, 巨噬细胞趋化因子-1(MCP-1)、转化生长因子-β₁ (TGF-β₁) 免疫组织化学染色, 应用图像分析系统进行免疫组化半定量分析。结果:联合组与单独用药组比较能有效降低阿霉素肾病大鼠血压[ 模型组(141±5) mm Hg,PTX 组(134± 6) mm Hg, ACEI 组(130±5) mm Hg, 联合治疗组(126±5) mm Hg]。各治疗组均显著降低蛋白尿, ACEI 组疗效略优于PTX组, 但差别无统计学意义;联合治疗组疗效优于单独治疗组(P<0.01), 且可以显著抑制MCP-1、TGF-β₁ 的表达(P<0.01)。结论:己酮可可碱、苯那普利及两药联用可更好地保护阿霉素肾病大鼠, 其机制与其降低尿蛋白、抑制肾脏炎症及抗肾间质纤维化有关。

关键词: 阿霉素, 肾病, 苯那普利, 己酮可可碱, 联合治疗, 巨噬细胞趋化因子-1, 转化生长因子-β₁

Abstract: AIM: To investigate the renoprotective effect of benazepril and pentifylline on adriamycin nephropathy rats.METHODS: A total 42 rats were randomly assigned to control group, model group, benazepril treatment group, pentifylline treatment group and combined treatment group.At the 8th week after operation, changes of the 24 hours urinary protein excretion, renal function, TP and Alb were also examined. Immunohistochemistry was performed to investigate renal pathological changes and the expression of MCP-1 and TGF-β₁.RESULTS: Combined treatment group could efficiently lowe the blood pressure [ PTX group (134±6) mm Hg, ACEI group(130±5) mm Hg, combined treatment group(126±5) mm Hg, control group(141±5) mm Hg] and the contents of proteinuria in treatment groups were decreased, the effect in ACEI group surpassed that in PTX group, but had no significance.The proteinuria in combined group was lowered than in single treatment group (P<0.01). Combined treatment group could efficiently decreased the expression of MCP-1 and TGF-β₁.CONCLUSION: Benazepril and pentifylline may play a protective role by depressing renal inflammation, interstitial fibrosis and lowering proteinuria.The effect of combination of benazepril and pentifylline is better than that of either.

Key words: adriamycin, nephronia, benazepril, pentifylline, combination, macrophage chemoattractant protein 1, transforming growth factor-β₁

中图分类号:

R965.1

杨沿浪, 张道友, 汪向明, 崔明春, 吴小东. 苯那普利及己酮可可碱对阿霉素肾病大鼠的肾脏保护作用[J]. 中国临床药理学与治疗学, 2009, 14(7): 736-740.

YANG Yan-lang, ZHANG Dao-you, WANG Xiang-ming, CUI Ming-chun, WU Xiao-dong. Renoprotective effect and mechanisms of benazepril and pentifylline on adriamycin nephropathy rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(7): 736-740.

参考文献

[1] Lin SL, Chen YM, Chien CT, et al.Pentoxifylline attenuated the renal disease progression in rats with renmant kidney [J].JASN, 2002, 13(12):2916-2929.
[2] Benigni A, Remuzzi G.How renal cytokines and growth factor contribute to renal disease progression [J].Am J Kindney Dis, 2001, 37(Suppl 2):S21-24.
[3] Abbate M, Zoja C, Morigi M, et al.Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins:a central pathway in progressive glomerulosclerosis [J].Am J Pathol, 2002, 161(6):2179-2193.
[4] Chen YM, Lin SL, Chiang WC, et al.Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases [J].Kidney Int, 2006, 69 (8):1410-1415.
[5] Panzer U, Thaiss F, Zahner G, et al.Monocyte chemoattractant protein-l and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis [J].Kidney Int, 200l, 59(5):1762-1769.
[6] Taal MW, Zandi-Nejad K,Weening B, et al.Pminflammatory gene expression and macrophage recruitment in the rat remnant kidney [J].Kidney Int, 2000, 58 (4):1664-1676.
[7] Chen YM, Nq YY, Lin SL, et al.Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats [J]. Nephrol Dial Transplant, 2004, 19(5):1106-1115.
[8] 张道友, 杨沿浪, 徐海红, 等.血管紧张素系统阻断剂对慢性肾脏疾病患者血清Ang Ⅱ、TGF-β₁ 水平的影响 [J].安徽医学, 2007, 28(4):285-288.
[9] Ng YY, Chen YM, Tsai TJ, et al.Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats [J]. Am J Nephrol, 2008, 29(1):43-53.
[10] 周秋根, 郑法雷, 文煜冰, 等.己酮可可碱对肾小管上皮细胞转分化抑制作用的实验研究 [J].中国中西医结合肾病杂志, 2005, 6(1):883-889.
[11] 傅淑霞, 王希倩, 郝玉杰, 等.己酮可可碱对单侧输尿管梗阻大鼠肾间质纤维化的保护作用及其机制 [J].中国医师杂志, 2006, 8(5):580-583.
[12] QI W, Chen X, Polhill TS, et al.TGF-beta1 induces IL-8 andMCP-1 through a connective tissue growth factor-independent pathway [J].Am J Physiol Renal Physiol, 2006, 290(3):F703-709.

[1]	陈群, 朱和平, 袁小龙. 197例己酮可可碱注射液医嘱点评分析与医院合理用药监管模式探讨[J]. 中国临床药理学与治疗学, 2023, 28(8): 948-953.
[2]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.
[3]	金依依, 周科挺, 杨成成, 徐萍, 朱素燕. 蛇床子素抑制NF-κB和p38/MAPK改善糖尿病诱导的肾脏损伤[J]. 中国临床药理学与治疗学, 2022, 27(6): 622-631.
[4]	朱新如, 黄鑫. 硫酸吲哚酚在慢性肾病并发症中的作用[J]. 中国临床药理学与治疗学, 2022, 27(6): 672-679.
[5]	刘鹏, 王晨, 王昀, 邱新萍. 薯蓣皂苷抑制NF-κB信号通路改善尿酸诱导的肾小管上皮细胞炎性损伤的机制研究[J]. 中国临床药理学与治疗学, 2022, 27(10): 1099-1105.
[6]	丁雪明, 陈天鹏, 徐强, 何欢, 何明. 川芎嗪通过14-3-3γ/Bcl-2减轻阿霉素引起的心肌毒性[J]. 中国临床药理学与治疗学, 2021, 26(4): 361-367.
[7]	金乐, 蒋多晨, 陈洪晓, 刘苏, 陈昭琳, 居靖. 槲皮素通过GAS5调控GSK-3β/β-catenin逆转乳腺癌阿霉素耐药[J]. 中国临床药理学与治疗学, 2021, 26(12): 1344-1351.
[8]	刘鹏, 赵海玲, 申正日, 王晨, 王昀, 邱新萍, 李平. 糖肾方抑制TGF-β1/Smad3通路促进小鼠肾小管上皮细胞胆固醇流出[J]. 中国临床药理学与治疗学, 2021, 26(1): 1-9.
[9]	潘战和, 王馨, 苏安, 张鹏, 纪浩南, 王小梅. 基于Notch 1/NF-κB/STAT3通路探讨塞来昔布逆转NK/T细胞淋巴瘤细胞阿霉素耐药的作用机制[J]. 中国临床药理学与治疗学, 2020, 25(12): 1330-1336.
[10]	赵韶静，曾艳，李正东，张华. 左卡尼汀对大鼠糖尿病肾病的保护作用分析[J]. 中国临床药理学与治疗学, 2019, 24(3): 278-282.
[11]	方茜，屈强，肖湘成. 他克莫司治疗特发性膜性肾病研究进展[J]. 中国临床药理学与治疗学, 2019, 24(2): 228-234.
[12]	刘雷，李轶枭，万波，曾青. miR-200c通过激活Wnt/β-连环蛋白信号通路诱导膀胱癌细胞阿霉素耐药[J]. 中国临床药理学与治疗学, 2018, 23(5): 510-516.
[13]	姚佳，乔迪，郭鑫，崔昌萌. 桑叶中1-脱氧野尻霉素对糖尿病肾病大鼠的治疗作用[J]. 中国临床药理学与治疗学, 2018, 23(5): 517-523.
[14]	姜莉莉，毛利民，胡思佳，彭应枝. 肾衰宁颗粒对糖尿病肾病大鼠肾组织NF-kB及PPAR-gamma表达的影响[J]. 中国临床药理学与治疗学, 2018, 23(2): 132-137.
[15]	傅永锦，夏雪怡，张小牧，刘艳波，潘竞锵，吕俊华. 川芎嗪对糖尿病肾病大鼠下调HMGB1表达及降低RAGEs作用[J]. 中国临床药理学与治疗学, 2017, 22(8): 846-851.